Abstract
Aim: The aim of the study was to investigate hypoglycemic and hypolipidemic activities of aqueous extracts of Centaurium erythraea (CnE) and Ajuga iva (AjI) after daily oral dosing for 60 days in a rodent model of metabolic syndrome (MetS).
Materials and Methods: Meriones shawi rats were fed a high caloric diet and forced to limited physical activity for 180 days to develop obesity, hyperglycemia and hyperlipidemia (OHH) as a model of MetS. After administration of single oral doses of test substances [extracts of CnE (250 mg/kg) and AjI (150 mg/kg), and reference drug [glibenclamide (GLB; 3 mg/kg)] to OHH rats, plasma levels of glucose, insulin, Total Cholesterol (TC), and Triglycerides (TG) were measured. In the sub-chronic study, the effect of daily oral dosing of test substances for 60 days to OHH rats, on Body Weight (BW), plasma glucose, insulin, TC, Low Density Lipoprotein (LDL)-cholesterol, High Density Lipoprotein (HDL)-cholesterol, TG, and free fatty acids were determined; insulin resistance (IR as HOMA-IR and QUICKI) and atherosclerotic index were calculated. Results and Conclusion: Meriones shawi rats developed OHH, hyperinsulinemia, IR and dyslipidemia- typical components of MetS. Single doses of test substances decreased only hyperglycemia. In the sub-chronic study, the test substances reduced plasma glucose, insulin, TC and LDL-cholesterol, as well as HOMA-IR and atherosclerotic index (AjI-extract > CnE-extract > GLB); plasma level of TG decreased with AjI only. These two plants may have the potential to be used therapeutically in the treatment of diabetes and possibly MetS, since, previous toxicological studies have shown a wide margin of safety for AjI and CnE.Keywords: Ajuga iva, Centaurium erythraea, diabetes, hypoglycemia, hypolipidemia, insulin resistance, Meriones shawi.
The Natural Products Journal
Title:Hypoglycemic and Hypolipidemic Effects of Aqueous Extracts of Ajuga iva and Centaurium erythreae on a Rodent Model of Metabolic Syndrome
Volume: 7 Issue: 1
Author(s): Adel Tahraoui, Zafar H. Israili and Badiaa Lyoussi
Affiliation:
Keywords: Ajuga iva, Centaurium erythraea, diabetes, hypoglycemia, hypolipidemia, insulin resistance, Meriones shawi.
Abstract: Aim: The aim of the study was to investigate hypoglycemic and hypolipidemic activities of aqueous extracts of Centaurium erythraea (CnE) and Ajuga iva (AjI) after daily oral dosing for 60 days in a rodent model of metabolic syndrome (MetS).
Materials and Methods: Meriones shawi rats were fed a high caloric diet and forced to limited physical activity for 180 days to develop obesity, hyperglycemia and hyperlipidemia (OHH) as a model of MetS. After administration of single oral doses of test substances [extracts of CnE (250 mg/kg) and AjI (150 mg/kg), and reference drug [glibenclamide (GLB; 3 mg/kg)] to OHH rats, plasma levels of glucose, insulin, Total Cholesterol (TC), and Triglycerides (TG) were measured. In the sub-chronic study, the effect of daily oral dosing of test substances for 60 days to OHH rats, on Body Weight (BW), plasma glucose, insulin, TC, Low Density Lipoprotein (LDL)-cholesterol, High Density Lipoprotein (HDL)-cholesterol, TG, and free fatty acids were determined; insulin resistance (IR as HOMA-IR and QUICKI) and atherosclerotic index were calculated. Results and Conclusion: Meriones shawi rats developed OHH, hyperinsulinemia, IR and dyslipidemia- typical components of MetS. Single doses of test substances decreased only hyperglycemia. In the sub-chronic study, the test substances reduced plasma glucose, insulin, TC and LDL-cholesterol, as well as HOMA-IR and atherosclerotic index (AjI-extract > CnE-extract > GLB); plasma level of TG decreased with AjI only. These two plants may have the potential to be used therapeutically in the treatment of diabetes and possibly MetS, since, previous toxicological studies have shown a wide margin of safety for AjI and CnE.Export Options
About this article
Cite this article as:
Tahraoui Adel, Israili H. Zafar and Lyoussi Badiaa, Hypoglycemic and Hypolipidemic Effects of Aqueous Extracts of Ajuga iva and Centaurium erythreae on a Rodent Model of Metabolic Syndrome, The Natural Products Journal 2017; 7 (1) . https://dx.doi.org/10.2174/2210315506666161024122601
DOI https://dx.doi.org/10.2174/2210315506666161024122601 |
Print ISSN 2210-3155 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-3163 |
Call for Papers in Thematic Issues
Ayurvedic medicinal therapeutic approaches for inflammatory and neurodegenerative disorders
Usually, in our elderly population, neurodegenerative disorders occur due to neuron death. Alzheimer?s disease (AD) is an irreversible and progressive neurodegenerative disease. Dementia is the leading cause of AD, which affects about 30 million people worldwide. According to the World Alzheimer report 2018, a new case of dementia develops every ...read more
Recent Advances in Biotransformation of Bioactive Terpenoids using Aspergillus niger
Biotransformation is the reaction catalyzed by biological catalysts of either isolated enzymes or whole cell cultures of microorganisms. This process has been extensively applied in the conversion of bioactive terpenoids with high regio- and stereospecifity. This process has been also applied in the lead discovery and development. Aspergillus niger has ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis
Current Pharmaceutical Biotechnology Obstetric Anaesthesia and Obesity
Current Women`s Health Reviews Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Seaweed Proteins as a Source of Bioactive Peptides
Current Pharmaceutical Design COVID-19 Severity: Lung-Heart Interplay
Current Cardiology Reviews Protective Effects of Diuretics Against the Development of Cardiovascular Disease in Patients with Chronic Kidney Disease: A Systematic Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiac Stem Cell Regeneration in Metabolic Syndrome
Current Pharmaceutical Design Intermittent Transient Motor Aphasia Associated with Acute Lithium Toxicity: A Case Report and Brief Review
Current Drug Safety Prevalence and associated factors of sarcopenia in elderly subjects with amnestic mild cognitive impairment or Alzheimer disease.
Current Alzheimer Research Pathophysiology of Thrombosis and Potential Targeted Therapies in Antiphospholipid Syndrome
Current Vascular Pharmacology Anti-miRNA-23a Oligonucleotide Suppresses Glioma Cells Growth by Targeting Apoptotic Protease Activating Factor-1
Current Pharmaceutical Design The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets Atherogenic Versus Non-atherogenic Lipoprotein Profiles in Healthy Individuals. Is There a Need to Change Our Approach to Diagnosing Dyslipidemia?
Current Medicinal Chemistry Development of Clinical Trial Assessments for the Study of Interstitial Lung Disease in Patients who have Connective Tissue Diseases-Methodological Considerations
Current Rheumatology Reviews Percutaneous Treatment of Hydatid Liver Cyst
Recent Patents on Anti-Infective Drug Discovery The Physiology, Pathophysiology and Therapeutic Potential of Gap Junctions in Smooth Muscle
Current Drug Targets Acute Coronary Syndromes: A Role of Immune System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cardiovascular Disease and Dyslipidemia: Beyond LDL
Current Pharmaceutical Design Gene Expression Suggests Spontaneously Hypertensive Rats May Have Altered Metabolism and Reduced Hypoxic Tolerance
Current Neurovascular Research The Relationship Between Prolidase Activity and Atrial Electromechanical Changes in Patients with Paroxysmal Atrial Fibrillation
Combinatorial Chemistry & High Throughput Screening